In a follow-up analysis to the pivotal TOPAZ-1 study, which established the combination therapy of durvalumab (an ...

IMFINZI® (durvalumab) perioperative regimen improved event-free survival and overall survival across muscle-invasive bladder cancer patients regardless of complete pathology response status in ...

In a follow-up analysis to the pivotal TOPAZ-1 study, which established the combination therapy of durvalumab (an ...

Two-year EFS with perioperative durvalumab was 67.4% versus 58.5% in the group of patients who received FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) and placebo, with median EFS not ...

Patients with ovarian clear cell carcinoma (OCCC) whose tumors have specific mutations in the PPP2R1A gene were found to have ...

IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC ...

The new indication allows durvalumab, in combination with carboplatin and paclitaxel, to be used as a first-line treatment ...

Cambridge: AstraZeneca has received approval for Imfinzi (durvalumab) in the European Union (EU) for the treatment of adult ...

AstraZeneca Pharma India Limited on Tuesday, July 1, 2025, received approval from the Central Drugs Standard Control ...

AstraZeneca Pharma shares rose after the company received regulatory approval to expand the use of its cancer drug Imfinzi ...

The Phase II trial will compare progression-free survival in lung cancer patients treated according to their molecular subtypes.

Bangalore: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation ...